Literature DB >> 3791248

A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination.

F J Lejeune, G E Ghanem.   

Abstract

Current methods for cytostatic dosimetry in isolation perfusion of the limbs are based on either limb tissue volume (LTV) or body weight. None of them take into account the actual blood volume intra- and extracorporal, including even the blood leakage if any, in which the pharmacokinetics take place. The present study describes a method which allows the assessment of the actual exchangeable blood volume. The latter is calculated by a formula based on three hematocrit measurements. Thirty-one cases entered the study. Exchangeable limb blood volume representing the limb vascular bed was found to average 340 +/- 148 (SD) ml for upper limb perfusion and 768 +/- 279 and 621 +/- 454 ml for iliac and femoropopliteal perfusion, respectively. There was a good correlation between exchangeable limb blood volume and limb tissue volume (LTV, r = 0.7), a poor one with body weight (r = 0.3), and no correlation at all with body surface. Melphalan dosage was calculated per ml of blood and applied at 20 to 40 micrograms/ml. Comparison between calculated dose and concentration measured by high performance liquid chromatography showed a high correlation (r = 0.963). Since there was a correlation between exchangeable limb blood volume and LTV, it was possible to derive a conversion for melphalan dosage where 13 mg/liter corresponds to 20 micrograms/ml in upper limb perfusion and 10 mg/liter corresponds to 40 micrograms/ml in lower limb perfusion. Comparison between calculated melphalan dosage based on our method and the LTV method showed a large dispersion of values in the latter (12 to 18% coefficient of variation) while the dispersion given by the body weight-based method increased 2-fold (16 to 31% coefficient of variation). It is concluded that the present dosimetry method is the most suitable up to the present for accurate prediction of cytostatic concentration in isolation perfusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3791248

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.

Authors:  Georgia M Beasley; Paul Speicher; Christina K Augustine; Paul C Dolber; Bercedis L Peterson; Ketan Sharma; Paul J Mosca; Richard Royal; Merrick Ross; Jonathan S Zager; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2014-08-22       Impact factor: 5.344

2.  Hyperthermic isolation perfusion of the limbs with cytostatics after surgical excision of sarcomas.

Authors:  F J Lejeune; D Lienard; P Ewalenko
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

3.  In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.

Authors:  D Liénard; F J Lejeune; P Ewalenko
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

4.  [Technique and results of hyperthermic perfusion of the extremity in melanoma patients].

Authors:  G Omlor; F Bahmer; S Meessen; D Zang; G Feifel; H Zaun
Journal:  Langenbecks Arch Chir       Date:  1993

5.  Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.

Authors:  H F Rauschecker; H Foth; H C Michaelis; F Horst; W Gatzemeier; C Willenbrock; E Voth; G F Kahl
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

7.  Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

Authors:  H J Guchelaar; H J Hoekstra; E G de Vries; D R Uges; J W Oosterhuis; H Schraffordt Koops
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

Review 8.  Management of in-transit melanoma of the extremity with isolated limb perfusion.

Authors:  Douglas L Fraker
Journal:  Curr Treat Options Oncol       Date:  2004-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.